The global androgenetic alopecia market size was estimated at USD 2.7 billion in 2023 and is projected to reach 4.76 billion by 2030, growing at a CAGR of 8.45% from 2024 to 2030. The rising market demand is primarily driven by the increasing incidence of androgenetic alopecia (AGA) worldwide, which is prompting a surge in the need for effective therapeutic treatments.

For context, data released by the U.S. Department of Health and Human Services in December 2023 highlight the widespread impact of androgenic alopecia, with an estimated 30 million women and 50 million men affected annually. In women, the prevalence tends to increase notably after menopause, linking hormonal changes to disease onset. Besides this, the market is further supported by growing investment in research and development aimed at discovering new and improved therapeutic options, coupled with increasing healthcare spending in various regions around the globe.

The rising prevalence of androgenetic alopecia can be attributed to several lifestyle and demographic factors that are becoming more pronounced worldwide. Changes in lifestyle habits, including higher consumption of alcohol and tobacco, shifts toward unhealthy dietary patterns like increased intake of junk food, and elevated stress levels, are all contributing to hair loss incidences. Additionally, an aging population, with a growing proportion of elderly individuals, is further amplifying the prevalence of the condition.

In the United States alone, it is estimated that approximately 50 million men and 30 million women suffer from androgenetic alopecia, according to figures from the National Library of Medicine. Supporting this, a report from the International Society of Hair Restoration Surgery indicates that a significant percentage of men experience hair loss as they age: nearly 40% of men by the age of 35, 65% by 60 years, 70% by 80 years, and 80% by 85 years. These demographic trends, combined with lifestyle factors, are expected to drive sustained growth in the androgenetic alopecia therapeutics market over the coming years.

Key Market Trends & Insights:

• In 2023, North America emerged as the dominant region in the global androgenetic alopecia market, holding a substantial market share of 37.40%. This strong presence is attributed to factors such as higher healthcare awareness, advanced medical infrastructure, and widespread access to effective therapeutic treatments. Meanwhile, the Asia Pacific region is projected to experience notable growth in the androgenetic alopecia market during the period from 2024 to 2030. This anticipated expansion is driven by increasing healthcare expenditures, rising prevalence of hair loss conditions, and growing awareness about treatment options among the population in countries within this region.

• When the market is segmented by gender, the male segment accounted for the largest share, capturing 56.59% of the market in 2023. This reflects the higher incidence and demand for treatment among men suffering from androgenetic alopecia, which is often more pronounced and socially impactful in this group.

• In terms of treatment types, the pharmaceuticals segment dominated the market with an overwhelming revenue share of 98.37% in 2023. This indicates that pharmaceutical products, including topical solutions, oral medications, and other drug therapies, remain the primary choice for managing androgenetic alopecia globally.

• Looking at the end-use category, dermatology clinics led the market by accounting for the largest share of 56.59% in 2023. This highlights the importance of specialized clinical settings where patients seek professional diagnosis and treatment for hair loss conditions, underscoring the critical role of dermatologists in managing androgenetic alopecia.

Order a free sample PDF of the Androgenetic Alopecia Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 2.7 Billion

• 2030 Projected Market Size: USD 4.76 Billion

• CAGR (2024-2030): 8.45%

• North America: Largest market in 2023

Key Companies & Market Share Insights:

Some of the key established companies operating within the global androgenetic alopecia market include well-known industry leaders such as Johnson & Johnson Services, Inc., Cipla, Inc., Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc. These prominent players are actively engaging in strategic collaborations and partnerships with regional companies to broaden their geographic presence and expand their service offerings in different markets worldwide. This approach not only strengthens their market positioning but also enables them to tap into new customer bases across various regions.

In addition to these established giants, several emerging companies are making their mark in the androgenetic alopecia market. Notable examples include Lexington International, LLC, Freedom Laser Therapy, Inc.—known for its iRESTORE Hair Growth System, Curallux, LLC, and Apira Science, Inc., which markets the iGROW Laser device. These newer entrants are primarily focusing on building strong collaborations with a wide range of distribution channels to enhance the availability of their products.

A significant factor contributing to the growth potential of these emerging players is the increasing accessibility of devices and over-the-counter (OTC) products through e-commerce platforms. The widespread availability of such products online is expected to dramatically extend their reach, allowing them to connect with and serve customers on a global scale more efficiently. This trend reflects a broader shift toward digital sales channels in the healthcare and wellness sectors, providing new opportunities for market expansion and consumer engagement.

Key Players

• Johnson & Johnson Services, Inc.

• Cipla, Inc.

• Sun Pharmaceutical Industries Ltd.

• Merck & Co., Inc.

• Dr. Reddy’s Laboratories Ltd.

• Aurobindo Pharma

• Lexington Intl., LLC

• Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)

• Curallux, LLC

• Apira Science, Inc. (iGROW Laser)

• Theradome Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The androgenetic alopecia market is experiencing steady growth driven by the increasing prevalence of hair loss globally, rising awareness of treatment options, and ongoing advancements in therapeutics and technologies. Growing investments in research and development, along with expanding healthcare infrastructure and rising consumer focus on aesthetic and wellness products, are further fueling market expansion. Additionally, the increasing availability of treatments through diverse distribution channels, including e-commerce, is enhancing accessibility for patients worldwide. The market is expected to witness continued innovation and adoption, supported by demographic shifts and lifestyle factors contributing to the rising incidence of androgenetic alopecia.